Recent insider trends for Capricor Therapeutics, Inc. (NASDAQ:CAPR) have caught the attention of investors. Patters in insider activity can help analysts formulate an outlook for a stock. In the case of CAPR, the data has a lot to say about how the stock might perform going forward.
Institutions own 03.23% of Capricor Therapeutics, Inc. (CAPR)’s shares. The total value of these holdings, in millions, is $2. Among active positions in the latest quarter, 7 holders increased their positions by a total of 220059 shares, 11 holders decreased the positions by a total of 360005 shares, and 7 holders held their positions. This works out to a net decrease in ownership of 139946 shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 3 holders initiated new positions by a total of 3225 shares and 6 holders exited their positions by a total of 91096 shares. This nets out to a decrease of 87871 shares and is another bearish sign for CAPR.
Insider ownership increased by a total of 0 shares, which suggests that CAPR’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 3 buys , and ownership increased by a net of 1.18 million shares.
Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s short interest is 845400 shares, or 8.19% of the float. This represents a decrease of -8% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
Given what the insider ownership patterns are saying, it makes sense to consider the technicals to see if these pieces of information reach the same conclusion about the outlook for CAPR. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that CAPR is a Strong buy, which implies that CAPR is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Capricor Therapeutics, Inc. (NASDAQ:CAPR) is undervalued.